These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36414028)

  • 41. Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response.
    Wofford W; Kim J; Kim D; Janneh AH; Lee HG; Atilgan FC; Oleinik N; Kassir MF; Saatci O; Chakraborty P; Tokat UM; Gencer S; Howley B; Howe P; Mehrotra S; Sahin O; Ogretmen B
    Cell Rep; 2024 Aug; 43(8):114532. PubMed ID: 39046874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rational combination of immunotherapy for triple negative breast cancer treatment.
    Li CW; Lim SO; Hsu JL; Hung MC
    Chin Clin Oncol; 2017 Oct; 6(5):54. PubMed ID: 29129094
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) EXPRESSION IN TRIPLE NEGATIVE BREAST CANCER CASES IN BENIN CITY.
    Owolabi DO; Olu-Eddo AN; Ekanem VJ; Udoh MO; Ogunbiyi JO; Obaseki DE; Obahiagbon I; Asogwa K; Nwagoh B; Aniume O; Ugiagbe EE; Forae GD; Imasogie DE
    West Afr J Med; 2023 Dec; 40(12 Suppl 1):S35. PubMed ID: 38070139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer.
    Wang C; Xu YH; Xu HZ; Li K; Zhang Q; Shi L; Zhao L; Chen X
    J Nanobiotechnology; 2023 Dec; 21(1):476. PubMed ID: 38082443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
    Tian Y; Wang X; Zhao S; Liao X; Younis MR; Wang S; Zhang C; Lu G
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46626-46636. PubMed ID: 31751121
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Azim HA; Shohdy KS; Elghazawy H; Salib MM; Almeldin D; Kassem L
    Biomarkers; 2022 Dec; 27(8):764-772. PubMed ID: 35980714
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune checkpoints in aggressive breast cancer subtypes.
    Zawlik I; Gablo N; Szymanska B; Pawlowska Z; Chudobinski C; Chalubinska-Fendler J; Morawiec Z; Zielinska-Blizniewska H; Morawiec-Sztandera A; Kolacinska A
    Neoplasma; 2016; 63(5):768-73. PubMed ID: 27468881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ERα is a negative regulator of PD-L1 gene transcription in breast cancer.
    Liu L; Shen Y; Zhu X; Lv R; Li S; Zhang Z; Shi YG; Tan L
    Biochem Biophys Res Commun; 2018 Oct; 505(1):157-161. PubMed ID: 30241942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment.
    Yang ZY; Jiang CW; Zhang WL; Sun G
    J Transl Med; 2022 Jun; 20(1):276. PubMed ID: 35717238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer.
    Wang Y; Chen Y; Ji DK; Huang Y; Huang W; Dong X; Yao D; Wang D
    J Nanobiotechnology; 2024 Aug; 22(1):461. PubMed ID: 39090622
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
    Qiu Y; Yang Y; Yang R; Liu C; Hsu JM; Jiang Z; Sun L; Wei Y; Li CW; Yu D; Zhang J; Hung MC
    Oncogene; 2021 Aug; 40(31):4992-5001. PubMed ID: 34172932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].
    Zhang W; Xu GX; Li JJ; Liu X; Chen YJ; Zhang F
    Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):20-24. PubMed ID: 28072971
    [No Abstract]   [Full Text] [Related]  

  • 54. MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
    Maeda T; Hiraki M; Jin C; Rajabi H; Tagde A; Alam M; Bouillez A; Hu X; Suzuki Y; Miyo M; Hata T; Hinohara K; Kufe D
    Cancer Res; 2018 Jan; 78(1):205-215. PubMed ID: 29263152
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Yang H; Jin F; Zheng A
    Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.
    Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
    Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan.
    Wang Y; Zhang X; Xie X; Chen W; Li M; Diao D; Dang C
    Cancer Biol Ther; 2020 Dec; 21(12):1179-1190. PubMed ID: 33218268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histological spatial analysis on the induction of PD-L1
    Suzuki K; Ohe R; Kabasawa T; Kitaoka T; Kawai M; Motoi F; Futakuchi M
    Breast Cancer; 2023 Nov; 30(6):1094-1104. PubMed ID: 37792212
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.
    Chen C; Li S; Xue J; Qi M; Liu X; Huang Y; Hu J; Dong H; Ling K
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.